Adagene, Inc. (ADAG)
| Market Cap | 572.69M |
| Revenue (ttm) | 700,913 |
| Net Income (ttm) | -42.65M |
| Shares Out | 42.33M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $13.53 |
| Previous Close | $13.73 |
| Change ($) | -0.20 |
| Change (%) | -1.46% |
| Day's Open | 13.67 |
| Day's Range | 13.50 - 13.78 |
| Day's Volume | 4,896 |
| 52-Week Range | 11.11 - 31.83 |
SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...
-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement
SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...
- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery pro...
-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global ex...
SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disco...
SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...
Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.
Adagene, Inc. has filed to go public with an IPO on the NASDAQ.
Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the compa...
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
About ADAG
Adagene is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. We have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI, algorithms and ever-increasing big data in antibody sequence, structure, b... [Read more...]
| Industry Biotechnology | IPO Date Feb 9, 2021 |
| CEO Peter (Peizhi) Luo, Ph.D. | Employees 198 |
| Stock Exchange NASDAQ | Ticker Symbol ADAG |
Financial Performance
In 2020, Adagene's revenue was $700,913, an increase of 46.02% compared to the previous year's $480,000. Losses were -$42.40 million, 158.0% more than in 2019.